Summary
October 23, 2012 - Specialty pharmaceutical company ZS Pharma, Inc. has raised $46 million to advancedevelopment of ZS-9, a crystal form of zirconium silicate, designed to treat patients with kidney and liver disease.Alta Partners led the new round of financing, joined by new investors RiverVest Venture Partners, 3x5 Special Opportunity Partners and Salem Partners as well as current investor Devon Park Bioventures. The funding will allow ZS Pharma to proceed with pivotal trials for ZS-9 as it prepares for commercialization of the product.
Click Here
to read the full article
Click Here
to read the full article